BioSpace News Archive

Pathnostics, a leading precision diagnostic testing and development company, today announced that it will present a new Medicare-claims-based method to identify an uncoded novel diagnostic (NDx), Guidance® UTI, and an analysis that found significantly lower costs as compared to standard urine culture (SUC) in patients with complicated urinary tract infections (cUTIs).

Factor Bioscience Inc., a Cambridge -based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting to be held in Washington, D.C. from May 16-19, 2022.

PolarityTE to host conference call and webcast today, May 16, 2022 , at 8:30 a.m. ET.

Syros Pharmaceuticals today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.

A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference.

Imago BioSciences, Inc. announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in three upcoming investor conferences.

TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase platform, today announced a Phase 3 study evaluating the efficacy and safety of its lead therapeutic candidate, efzofitimod (ATYR1923), in patients with pulmonary sarcoidosis.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the year ended March 31, 2022, and provided a corporate update.